Is Ramucirumab Still the Only Second-Line Treatment in Metastatic Gastric Cancer?

References

• Rawla P , BarsoukA. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz. Gastroenterol.14(1), 26–38 (2019).
   PubMed Web of Science ®Google Scholar
• Bendell J , YoonHH. Initial systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer. (2020). https://ezproxy.usj.edu.lb:4555/contents/initial-systemic-therapy-for-locally-advanced-unresectable-and-metastatic-esophageal-and-gastric-cancer?search=gastric%20cancer&source=search_result&selectedTitle=9∼150&usage_type=default&display_rank=9
   Google Scholar
• Fanotto V , FornaroL , BordonaroRet al. Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: a multicentre real-world study. J. Geriatr. Oncol.10(4), 591–597 (2019).
   PubMed Web of Science ®Google Scholar
• Smyth EC , VerheijM , AllumW , CunninghamD , CervantesA , ArnoldD. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol.27, v38–49 (2016).
   PubMed Web of Science ®Google Scholar
• Ghosn M , TabchiS , KourieHR , TehfeM. Metastatic gastric cancer treatment: second-line and beyond. World J. Gastroenterol.22(11), 3069 (2016).
   PubMed Web of Science ®Google Scholar
• Wesolowski R , LeeC , KimR. Is there a role for second-line chemotherapy in advanced gastric cancer?Lancet Oncol.10(9), 903–912 (2009).
   PubMed Web of Science ®Google Scholar
• Pericay C , RiveraF , Gomez-MartinC , NuñezI , CassinelloA , ImedioER. Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma. Cancer Med.5(12), 3464–3474 (2016).
   PubMed Web of Science ®Google Scholar
• Murahashi S , TakahariD , WakatsukiTet al. A retrospective analysis of ramucirumab monotherapy in previously treated Japanese patients with advanced or metastatic gastric adenocarcinoma. Int. J. Clin. Oncol.23(1), 92–97 (2018).
   PubMed Web of Science ®Google Scholar
• Kang B , KwonO-K , ChungH , YuW , KimJ. Taxanes in the treatment of advanced gastric cancer. Molecules21(5), 651 (2016).
   PubMed Web of Science ®Google Scholar
• Lorenzen S , Thuss-PatiencePC , PauligkCet al. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy: interim safety and efficacy results from the Phase II RAMIRIS study (AIO-STO-0415) of the German Gastric Group at AIO. J. Clin. Oncol.37(Suppl. 15), 4023–4023 (2019).
   Web of Science ®Google Scholar
• Chung HC , ArkenauH-T , LeeJet al. Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: Phase Ib results from the JAVELIN Solid Tumor trial. J. Immunother. Cancer7(1), 30 (2019).
   PubMed Web of Science ®Google Scholar
• Alsina M , MoehlerM , HierroC , GuardeñoR , TaberneroJ. Immunotherapy for gastric cancer: a focus on immune checkpoints. Target Oncol.11(4), 469–477 (2016).
   PubMed Web of Science ®Google Scholar
• Kang Y-K , BokuN , SatohTet al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, Phase III trial. Lancet390(10111), 2461–2471 (2017).
   PubMed Web of Science ®Google Scholar
• Fuchs CS , DoiT , JangRWet al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase II clinical KEYNOTE-059 trial. JAMA Oncol.4(5), e180013–e180013 (2018).
   PubMed Web of Science ®Google Scholar
• Crew KD , NeugutAI. Epidemiology of gastric cancer. World J. Gastroenterol.12(3), 354 (2006).
   PubMed Web of Science ®Google Scholar
• Shitara K , ÖzgüroğluM , BangYJet al. KEYNOTE-061: Phase III study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer. Ann. Oncol.29, v123 (2018).
   Web of Science ®Google Scholar
• Hironaka S , KadowakiS , IzawaNet al. A Phase I/II study of nivolumab, paclitaxel, and ramucirumab as second-line in advanced gastric cancer. J. Clin. Oncol.38(Suppl. 4), 352–352 (2020).
   Web of Science ®Google Scholar
• Bang Y-J , GolanT , LinC-Cet al. Ramucirumab (Ram) and durvalumab (Durva) treatment of metastatic non-small-cell lung cancer (NSCLC), gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, and hepatocellular carcinoma (HCC) following progression on systemic treatment(s). J. Clin. Oncol. (37(15), 2528–2528 (2020).
   Web of Science ®Google Scholar
• Koemans WJ , ChalabiM , van SandickJW , van DierenJM , KodachLL. Beyond the PD-L1 horizon: in search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma. Cancer Lett.442, 279–286 (2019).
   PubMed Web of Science ®Google Scholar
• Valentini A , DiPinto F , ColettaS , GuerraV , ArmentanoR , CarusoM. Tumor microenvironment immune types in gastric cancer are associated with mismatch repair however, not HER2 status. Oncol. Lett (18(2), 1775–1785 (2019).
   PubMed Web of Science ®Google Scholar
• Lee V , MurphyA , LeDT , DiazLA. Mismatch repair deficiency and response to immune checkpoint blockade. Oncologist21(10), 1200–1211 (2016).
   PubMed Web of Science ®Google Scholar
• Vrána D , MatzenauerM , NeoralČet al. From tumor immunology to immunotherapy in gastric and esophageal cancer. Int. J. Mol. Sci.20(1), 13 (2018).
   PubMed Web of Science ®Google Scholar
• Giampieri R , MaccaroniE , MandolesiAet al. Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy. Gastric Cancer20(1), 156–163 (2017).
   PubMed Web of Science ®Google Scholar
• Dolcetti R , DeRe V , CanzonieriV. Immunotherapy for gastric cancer: time for a personalized approach?Int. J. Mol. Sci.19(6), 1602 (2018).
   PubMed Web of Science ®Google Scholar
• Chao J , FuchsCS , ShitaraKet al. Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GEJ) cancer by line of therapy. J. Clin. Oncol.38(Suppl. 4), 430–430 (2020).
   Web of Science ®Google Scholar
• Fashoyin-Aje L , DonoghueM , ChenHet al. FDA approval summary: pembrolizumab for recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing PD-L1. Oncologist24(1), 103–109 (2019).
   PubMed Web of Science ®Google Scholar
• Zaanan A , TaiebJ. How to better select patients with advanced gastric cancer for immunotherapy. Transl. Gastroenterol. Hepatol.4, 6–6 (2019).
   PubMed Web of Science ®Google Scholar
• Kwak Y , SeoAN , LeeHE , LeeHS. Tumor immune response and immunotherapy in gastric cancer. J. Pathol. Transl. Med.54(1), 20–33 (2020).
   PubMed Web of Science ®Google Scholar
• Bang Y-J , CutsemEV , FeyereislovaAet al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a Phase III, open-label, randomised controlled trial. Lancet376(9742), 687–697 (2010).
   PubMed Web of Science ®Google Scholar
• Li Q , JiangH , LiHet al. Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study. Oncotarget7(31), 50656–50665 (2016).
   PubMedGoogle Scholar
• Bang Y-J . A randomized, open-label, Phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population: tytan study. J. Clin. Oncol.31(Suppl. 4), 11–11 (2013).
   PubMed Web of Science ®Google Scholar
• Nishikawa K , TakahashiT , TakaishiHet al. Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane- and trastuzumab-naïve patients with HER2-positive, previously treated, advanced, or recurrent gastric cancer (JFMC45-1102): advanced or recurrent gastric cancer (JFMC45-1102). Int. J. Cancer140(1), 188–196 (2017).
   PubMed Web of Science ®Google Scholar
• Bendell J , YoonHH. Progressive, locally advanced unresectable, and metastatic esophageal and gastric cancer: approach to later lines of systemic therapy. (2020). https://ezproxy.usj.edu.lb:4555/contents/progressive-locally-advanced-unresectable-and-metastatic-esophageal-and-gastric-cancer-approach-to-later-lines-of-systemic-therapy?search=gastric%20cancer&source=search_result&selectedTitle=3∼150&usage_type=default&display_rank=3#H81501608
   Google Scholar
• Astor L . FDA approves frontline pembrolizumab for MSI-H/dMMR CRC. (2020). https://www.targetedonc.com/view/fda-approves-frontline-pembrolizumab-for-msi-h-dmmr-crc
   Google Scholar